

A2
Concl'd.

sequence selected from the group consisting of SEQ. ID No. 4 and SEQ. ID No. 6 in a physiologically acceptable carrier or diluent.

4. (Amended) The pharmaceutical composition [as set forth in claim 1] of a synthetic nuclease resistant antisense oligodeoxynucleotide comprising either SEQ. ID No. 4 or SEQ. ID No. 6 and at least one other non-control AS-ODN selected from Tables 1 and 2 wherein a percent inhibition is greater than 25%.

✓ ✓
Claim 5, line 2, please delete "capable of" and insert therefor
--for--.

A2 *B*
SUB C2

7. (Amended) A pharmaceutical composition for selectively ^{*inhibiting*} [modulating] ~~regulating~~ mammalian [tumor] tumor necrosis factor alpha in a mammal in need of such treatment consisting of
an effective amount of at least one active ingredient [as set forth in claim 1] a synthetic nuclease resistant antisense oligodeoxynucleotide having a nucleotide sequence selected from the group consisting of SEQ. ID No. 4 and SEQ. ID No. 6 in a pharmaceutically physiologically acceptable carrier or diluent.

A4
Cont'd. *B*
SUB C3

13. (New) A method of selectively regulating mammalian tumor necrosis factor alpha by the steps of targeting for treatment the tumor necrosis factor alpha splice region and then specifically modify the region to ^{*inhibit*} ~~regulate~~ the mammalian tumor necrosis factor alpha.

14. (New) The method of claim 13 further including the step of administering an effective amount of a synthetic nuclease resistant antisense oligodeoxynucleotide which targets exon sequences flanking donor splice sites.

15. (New) A method of inhibiting tumor necrosis factor alpha by targeting for treatment the tumor necrosis factor alpha splice region.